2021 International Liver Transplantation Society (ILTS)-SETH Consensus Conference

Target Audience: • Surgeons • Hepatologists • Pathologists • Radiologists • Oncologists • Scientists • Nurses This conference will focus on non-hepatic cancer in the liver transplant setting. Post-transplant malignancy has become a significant cause of...
Hepatology Transplant Sur...
Target Audience: • Surgeons • Hepatologists • Pathologists • Radiologists • Oncologists • Scientists • Nurses This conference will focus on non-hepatic cancer in the liver transplant setting. Post-transplant malignancy has become a significant cause of mortality. In addition, an increasing number of patients with a history of pre-existing non-hepatic malignancies are being considered for liver transplantation. Careful selection of those with the lowest risk of recurrence, tailored screening, and management with new oncological therapies should be developed and will be discussed by a multidisciplinary set of experts from all over the world. Topic: Non-hepatic Cancer and Liver Transplantation: Shifting the Paradigm. Dropping the Cancer Stigma ,Expected Educatonal Outcomes: The participants will be able to review and discuss the most updated research regarding non-hepatic malignancy in the candidate, the donor or the recipient, including selection criteria/ indications, prognostic models, surveillance strategies, novel therapies and management. The participants will gain insight into innovations that lead to improvement in the field of liver transplantation in candidates or donors with a history of malignancy, and in recipients with de novo cancer, both in adult and pediatric population. ,Learning Objectives: • Understand the gap between current practice and future transplant related oncology. • Update selection criteria and prediction models in candidates with a history of prior malignancy in remission. • Identify who is safe to donate a liver with a history of cancer or with a cancer detected during transplant work-up. • Identify novel biologic, chemotherapeutic, radiologic, and immunotherapeutic approaches for patients with de novo cancer developing after liver transplantation. ,Additional details will be posted as soon as information is available.
support@emedevents.com
1(800) 828-2059
Valencia, Valencia